ResMed Statement on Brightree Executive Appointments
- Brightree announced new CEO Matt Mellott and new COO Bobby Ghoshal this morning
- Mellott, an HME industry veteran, joins Brightree following more than a decade at MedBridge Healthcare, a multi-state sleep diagnostic and respiratory therapy provider
- Current Brightree president and CEO Dave Cormack will transition into a multi-year advisory role
- ResMed acquired Brightree in April 2016
- Brightree will continue to operate as a separate entity; managed independently from its Atlanta headquarters
SAN DIEGO, June 20, 2016 /PRNewswire/ -- ResMed (NYSE:RMD) today issued the following statement related to Brightree's announcement of its new executive team, from president of healthcare informatics Raj Sodhi:
"Matt Mellott and Bobby Ghoshal join an exceptional senior leadership team with a commitment to customer-centered innovation and a culture of excellence. They will continue moving Brightree forward, expanding on the company's leadership in business management and clinical software applications for the post-acute care industry."
"Brightree wouldn't be the company it is today without the leadership of Dave Cormack, whose tenure as president and CEO began in 2005. We're pleased Dave has agreed to stay on in an advisory role to ensure a smooth transition."
"ResMed and Brightree will continue to shape the frontier of digital health. Their innovations in software, informatics and devices will continue to improve patients' quality of life, slow the progression of chronic diseases and lower overall healthcare system costs while enabling HMEs and other post-acute care providers to better manage their businesses and optimize patient care."
About ResMed
ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 1 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
|
For media: |
For investors: |
|
Alison Graves |
Agnes Lee |
|
Director, Corporate Communications |
Senior Director, Investor Relations |
|
O: 858-836-6789 |
O: 858-836-5971 |
Logo - https://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/resmed-statement-on-brightree-executive-appointments-300286850.html
SOURCE ResMed Inc.
Released June 20, 2016